Home › Recently closed › 2026-17380
International Drug Scheduling; Single Convention on Narcotic Drugs; Convention on Psychotropic Substances; Clobromazolam (Phenazolam); Cychlorphine (N-Propionitrile Chlorphine); Desalkylgidazepam (Bromonordiazepam); Ethylbromazolam; Etomethazene (5-Methyl Etodesnitazene); Spirochlorphine (R6980); Etomidate; Medetomidine; Request for Comments
Read on FederalRegister.gov · Official PDF · Docket on Regulations.gov · Add to calendar (.ics)
Summary (from the Federal Register abstract)
The Food and Drug Administration (FDA or Agency) is providing interested persons with the opportunity to submit comments concerning abuse potential, actual abuse, medical usefulness, trafficking, and impact of scheduling changes on availability for medical use of eight drug substances. These comments will be considered in preparing a response from the United States to the Expert Committee on Drug Dependence (ECDD) regarding the abuse liability and diversion of these drugs. The ECDD will use this information to consider whether to recommend that certain international restrictions be placed on these drug substances. This notice requesting comments is required by the Controlled Substances Act (CSA).
- Document type
- Notice
- Federal Register document number
- 2026-17380
- Published
- Aug 26, 2026
- Action
- Notice; request for comments.
- Docket
- FDA-2026-N-9208
- Comments posted on Regulations.gov (at last check)
- 3
- DATES section (from the document)
- Either electronic or written comments must be submitted by September 3, 2026.
- Topics (auto-tagged)
- Other FDA topics
Source: Federal Register API, document 2026-17380. Federal Register text is a U.S. government work. Confirm dates in the official document; later documents may extend, reopen or correct them.